Pay in 4 interest-free payments of $6.81 Learn more
Ships within 48 hours · Estimated delivery Sep 28 - Oct 3
BPC 157
Lifestyle & Emotional Care Identify and reduce stressors Breathwork (especially alternate nostril breathing) Acupuncture or vagus nerve support Temperature regulation avoid hot yoga, steam rooms and cold showers/plunges Gentle cardio over high-intensity (less facial flushing) Yoga or walking in cooler environments
At baseline, most patients (97%) were treated with one or more glucose-lowering medications, including metformin (76%), insulin (51%), SGLT-2i (27%), sulfonylurea (29%), and DPP-4i (23%) with CV disease and risk factors managed with lipid-lowering medications (89%), platelet-aggregation inhibitors including aspirin (77%), angiotensin converting enzyme inhibitors or angiotensin II receptor blockers (79%), and beta blockers (64%)
In an announcement published on 21 May 2026, Eli Lilly shared the results of the TRIUMPH-1 study, which involved 2,339 participants who were randomised to receive either retatrutide 4mg, 9mg, 12mg (building up every four weeks from 2mg), or placebo
